Evidence map›Paper›PMID 29729393›Full record

Trial reportNeuroImage2018

Time course of clinical change following neurofeedback.

Mariela Rance, Christopher Walsh, Denis G Sukhodolsky, Brian Pittman, Maolin Qiu, Stephen A Kichuk, Suzanne Wasylink, William N Koller, Michael Bloch, Patricia Gruner and 3 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in NeuroImage, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Targeting the affective brain-a randomized controlled trial of real-time fMRI neurofeedback in patients with depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Trial

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mariela RanceDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06520, USA.
Christopher WalshDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06520, USA.
Denis G SukhodolskyChild Study Center, Yale University School of Medicine, New Haven, CT 06519, USA.
Brian PittmanDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT 06511, United States.
Maolin QiuDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06520, USA.
Stephen A KichukDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT 06511, United States.
Suzanne WasylinkDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT 06511, United States.
William N KollerDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06520, USA.
Michael BlochDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT 06511, United States.
Patricia GrunerDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT 06511, United States.
Dustin ScheinostDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06520, USA; Child Study Center, Yale University School of Medicine, New Haven, CT 06519, USA.
Christopher PittengerChild Study Center, Yale University School of Medicine, New Haven, CT 06519, USA; Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06511, United States; Department of Psychology, Yale University, New Haven, CT 06520, USA.
Michelle HampsonDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, CT 06520, USA; Child Study Center, Yale University School of Medicine, New Haven, CT 06519, USA; Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06511, United States. Electronic address: michelle.hampson@yale.edu.

Funding

Biofeedback of activity in the orbitofrontal cortex for OCDR01MH100068 · NIMH · YALE UNIVERSITY · PI HAMPSON, MICHELLE · 2014 to 2018
$2.5M
Biofeedback of activity in the supplementary motor area for Tourette SyndromeR01MH095789 · NIMH · YALE UNIVERSITY · PI HAMPSON, MICHELLE · 2012 to 2016
$2.1M
Neurobiology of Behavior Therapy for Children with Tourette SyndromeK01MH079130 · NIMH · YALE UNIVERSITY · PI SUKHODOLSKY, DENIS G · 2008 to 2012
$833k
Dissecting Causal Reasoning Abnormalities in Obsessive-Compulsive Disorder (OCD)K23MH115206 · NIMH · YALE UNIVERSITY · PI GRUNER, PATRICIA A. · 2018 to 2021
$788k
NIH HHS K01 MH079130NIH HHS R01 MH095789NIH HHS R01 MH100068NIMH NIH HHS K01 MH079130NIMH NIH HHS K23 MH115206NIMH NIH HHS R01 MH095789NIMH NIH HHS R01 MH100068
6 · The paper itself

Abstract

Neurofeedback - learning to modulate brain function through real-time monitoring of current brain state - is both a powerful method to perturb and probe brain function and an exciting potential clinical tool. For neurofeedback effects to be useful clinically, they must persist. Here we examine the time course of symptom change following neurofeedback in two clinical populations, combining data from two ongoing neurofeedback studies. This analysis reveals a shared pattern of symptom change, in which symptoms continue to improve for weeks after neurofeedback. This time course has several implications for future neurofeedback studies. Most neurofeedback studies are not designed to test an intervention with this temporal pattern of response. We recommend that new studies incorporate regular follow-up of subjects for weeks or months after the intervention to ensure that the time point of greatest effect is sampled. Furthermore, this time course of continuing clinical change has implications for crossover designs, which may attribute long-term, ongoing effects of real neurofeedback to the control intervention that follows. Finally, interleaving neurofeedback sessions with assessments and examining when clinical improvement peaks may not be an appropriate approach to determine the optimal number of sessions for an application.

Indexed as

Outcome Assessment, Health CareAdolescentAdultFunctional NeuroimagingHumansMagnetic Resonance ImagingMiddle AgedMind-Body TherapiesNeurofeedbackObsessive-Compulsive DisorderPattern Recognition, VisualPrefrontal CortexTime FactorsTourette Syndrome

Identifiers

PMID29729393
PMCPMC6454268

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.